ReviewAnnals of neurology2013
Therapeutic advances in muscular dystrophy.
Review in Annals of neurology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- Effectiveness of conservative non-pharmacological interventions in people with muscular dystrophies: a systematic review and meta-analysis.Journal of neurology, neurosurgery, and psychiatry · 2024Pooled it
- Article
- Molecular Biology of ACL Graft Healing: Early Mechanical Loading Perspective.Orthopedic reviews · 2025Article
- Reduced myotube diameter induced by combined inhibition of transforming growth factor-β type I receptors Acvr1b and Tgfbr1 is associated with enhanced β1-syntrophin expression.Journal of cellular physiology · 2024Article
- Development of a local controlled release system for therapeutic proteins in the treatment of skeletal muscle injuries and diseases.Cell death & disease · 2024Article
- A Systematic Review on the Application of Virtual Reality for Muscular Dystrophy Rehabilitation: Motor Learning Benefits.Life (Basel, Switzerland) · 2024Review
- An implantable soft robotic ventilator augments inspiration in a pig model of respiratory insufficiency.Nature biomedical engineering · 2023Article
- Synthesis of SMT022357 enantiomers andTetrahedron · 2020Article
- Analysis of Different Device Interactions in a Virtual Reality Task in Individuals With Duchenne Muscular Dystrophy-A Randomized Controlled Trial.Frontiers in neurology · 2019Article
- Preliminary Evidences of Safety and Efficacy of Flavonoids- and Omega 3-Based Compound for Muscular Dystrophies Treatment: A Randomized Double-Blind Placebo Controlled Pilot Clinical Trial.Frontiers in neurology · 2019Article
- NS-065/NCNP-01: An Antisense Oligonucleotide for Potential Treatment of Exon 53 Skipping in Duchenne Muscular Dystrophy.Molecular therapy. Nucleic acids · 2018Article
- Galectin-3 and N-acetylglucosamine promote myogenesis and improve skeletal muscle function in the mdx model of Duchenne muscular dystrophy.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2018Article
- Hydrogel biomaterials and their therapeutic potential for muscle injuries and muscular dystrophies.Journal of the Royal Society, Interface · 2018Review
- Transplantation of Allogeneic PW1JACC. Basic to translational science · 2017Article
- Nutraceuticals and Their Potential to Treat Duchenne Muscular Dystrophy: Separating the Credible from the Conjecture.Nutrients · 2016Review
- Trends in steroid therapy for Duchenne muscular dystrophy in Japan.Muscle & nerve · 2016Article
- A first-line diagnostic assay for limb-girdle muscular dystrophy and other myopathies.Human genomics · 2016Article
- Clinical trial network for the promotion of clinical research for rare diseases in Japan: muscular dystrophy clinical trial network.BMC health services research · 2016Article
- Circulating miRNAs are generic and versatile therapeutic monitoring biomarkers in muscular dystrophies.Scientific reports · 2016Article
- Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy.EMBO molecular medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The muscular dystrophies comprise a heterogeneous group of genetic disorders that produce progressive skeletal muscle weakness and wasting. There has been rapid growth and change in our understanding of these disorders in recent years, and advances in basic science are being translated into increasing numbers of clinical trials. This review will discuss therapeutic developments in 3 of the most common forms of muscular dystrophy: Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and myotonic dystrophy. Each of these disorders represents a different class of genetic disease (monogenic, epigenetic, and repeat expansion disorders), and the approach to therapy addresses the diverse and complex molecular mechanisms involved in these diseases. The large number of novel pharmacologic agents in development with good biologic rationale and strong proof of concept suggests there will be an improved quality of life for individuals with muscular dystrophy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.